

# INDEX

## Volume Seven January through December 1973

### DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages 1 - 48
February	Pages 49 - 96
March	Pages 97 - 144
April	Pages 145 - 192
May	Pages 193 - 240
June	Pages 241 - 288

July	Pages 289 - 328
August	Pages 329 - 368
September	Pages 369 - 432
October	Pages 433 - 480
November	Pages 481 - 528
December	Pages 529 - 584

#### A

**Acetaminophen**, immune thrombocytopenia (ab) 45

**Adverse Drug Reactions**

amitriptyline, cardiotoxicity (ab) 46

analgesic nephropathy, ureteric stricture (ab) 425

anaphylactic shock, 394

antibiotic therapy, candida endocarditis (ab) 362

anticonvulsants, lupus-like disease (ab) 186

anticonvulsants, vitamin D metabolism (ab) 479

antipsychotics, tardive dyskinesia (ab) 478

arginine, anaphylactic reaction (ab) 186

aspirin, asthma (ab) 187

aspirin, peptic ulcer (ab) 280

azathioprine, SLE exacerbation (ab) 186

calcium carbonate, hypercalcemia (ab) 425

carbenicillin, granulocytopenia (ab) 281

cephalosporins, agranulocytosis (ab) 478

cephalosporins, renal and/or hepatic insufficiency, 252

cephalothin, anaphylaxis (ab) 361

cephalothin, meningitis (ab) 324

children, 106

chloromethyl methyl ether, lung cancer (ab) 325

clindamycin, colitis (ab) 281

clindamycin, Stevens-Johnson syndrome (ab) 186

clofibrate, acute muscular syndrome (ab) 95

contraceptives, hemolytic uremic syndrome (ab) 524

corticosteroids, simulated glaucoma (ab) 94

cyclophosphamide, water intoxication (ab) 425

dapsone, peripheral neuropathy (ab) 140

deafness, drug-induced (ab) 325

dexamethasone, transient reaction (ab) 142

diazepam, aberrant response (ab) 185

diazepam, thrombophlebitis (ab) 186

diphenylhydantoin, teratogenicity (ab) 186

diuretics, interstitial nephritis (ab) 186

duck embryo rabies vaccine (ab) 324

epidemiology of (ab) 89

erythromycin, biliary colic (ab) 141

estrogens, hemolytic uremic syndrome (ab) 524

ferrous sulfate (ab) 324

fluroxene, jaundice (ab) 141

gallamine, hazards of retention (ab) 141

glutethimide, osteomalacia (ab) 362

halothane, lymphocyte function tests (ab) 141

hydrochlorothiazide, pneumonitis (ab) 281

iron, dermatitis (ab) 422

iron, sarcoma (ab) 423

isoniazid, hepatitis (ab) 479

levodopa, metabolic responses (ab) 46

levodopa therapy, start hesitation (ab) 361

lidocaine, sinus standstill (ab) 187

lithium, in pregnancy (ab) 422

lithium, acute brain syndrome (ab) 141

lithium, myocardial irritability (ab) 95

LSD users, reproductive detriment (ab) 142

measles vaccination (ab) 281

methimazole, jaundice (ab) 235

methotrexate, neurotoxicity (ab) 524

methoxyflurane, renal failure (ab) 236

methyldopa, hepatitis (ab) 362

methyglucamine, hyperosmolality (ab) 142

nafcillin, nephritis (ab) 479

narcotic addiction, hyperimmunoglobulinemia (ab) 281

nickel salts, asthma (ab) 423

oral contraceptives (ab) 425

oral contraceptives, blood pressure (ab) 94

oral contraceptives, breast lesions (ab) 324

oral contraceptives, hemolytic uremic syndrome (ab) 425

penicillin, anaphylaxis (ab) 361

penicillin, bone marrow (ab) 325

penicillin, in venereal disease (ab) 280

phenacyclidine, psychosis (ab) 574

podophyllum (ab) 235

prednisone, dosage (ab) 95, 235

prednisone, extrapyramidal symptoms (ab) 324

prilocaine, methemoglobinemia (ab) 94

procainamide, arrhythmias, 271

procarbazine, allergic reaction (ab) 95

propoxyphene (ab) 236

propranolol, agranulocytosis (ab) 281

propylthiouracil, hypoproteinememia (ab) 142

rabies vaccine, duck embryo (ab) 324

salicylates (ab) 324

sterility, drug-induced (ab) 281

thioridazine, agranulocytosis and hepatitis (ab) 325

trifluoperazine, extrapyramidal symptoms (ab) 324

vincristine, seizures (ab) 478

**Advertising**, drug, comparison in two Finnish medical journals (ab) 360

Aikman, Jane (author) abstracts, 95

Alcoholism, in women (ab) 88

Aldosterone, increased by thiazides, 506

Alkalosis, 507

Allergy, anaphylactic shock, 394

Amantadine, in Parkinson's (ab) 43

Amerson, Ann B. (co-author) Letter concerning IV filters, 419

Aminophylline, review of clinical use, 156; IV incompatibility, 156

Amitriptyline, cardiotoxicity (ab) 46; overdose, case study, 451; letter of correction, 570

Amoxicillin, in urinary tract infections, 525

Amphotericin B, intrathecal therapy (ab) 237

Ampicillin, in renal and hepatic insufficiency, 62

**Analgesic Nephropathy**, ureteric stricture (ab) 425

**Analgesics**, 208

Anaphylaxis, 394

ANCEF, See Cefazolin

Anesthetics, compounding of local (ab) 93

**Antibiotics**

candida endocarditis (ab) 362

in gonorrhea, 205

in renal and hepatic insufficiency, penicillins, 62; cephalosporins, 252; aminoglycosides, 540

**Anticoagulants**, therapy in myocardial infarction, 202

**Anticonvulsants**

follic acid, and epilepsy (ab) 422

induced antinuclear antibodies and lupus-like disease (ab) 186

vitamin D metabolism, abnormal (ab) 479

**Antihypertensive Agents**, 208

**Antiparkinson Agents**, reversal of drug toxicity (ab) 427

**Antipsychotic Drugs**, tardive dyskinesia from (ab) 478

Apomorphine, in poisonings (ab) 326

Arena, James (co-author) Diazoxide, evaluation of, 459

Arginine, anaphylactic reaction (ab) 186

Ascorbic Acid, effects on serum glucose values (ab) 323; warfarin (ab) 46

**Aspirin**

asthma (ab) 187

atherosclerosis & myocardial infarction (ab) 91

peptic ulcer (ab) 280

sedative (ab) 188

Auto-experimentation (ab) 360

Avlosulfon, See Dapsone

Azathioprine, SLE exacerbation after discontinuing therapy (ab) 186

#### B

Bachman, Sister Janice (author) IV Admixture

Service Policy & Procedure Manual, 84

Barbiturates, intoxication, 309

Barker, Kenneth N. (author) Interim Report of National Coordinating Committee on Large Volume Parenteral Solutions, 475

Barriere, Steven L. (author) Letter regarding cephalothin dosage in renal impairment, 526

BCG, leukemia mortality (ab) 91

Benzhexol, interaction with fluphenazine therapy (ab) 93

**Benzodiazepines**, interactions with warfarin (ab) 93

Bicarbonate, effect of thiazides on serum electrolytes, 506

**Bioavailability**

chlorpromazine hydrochloride, 408

data, pharmacist's dilemma in using for product selection, 444 (ed.) 443

data, summary of acceptable, 448

digoxin tablets, 78; (ab) 525

dissolution relationships (ab) 525

statement by Pharmaceutical Society of Great Britain, 116; (ed.) 105

therapeutic activity of drugs, 168

**Biological Half-Lives**, See Half-Lives

**Biopharmaceutic Data**, See also Pharmacokinetics

diazoxide, 461

use of for product selection, 444

Blalock, Carole Cranor (author) Drug Evaluation, Triclofos, 126

Bones, radionuclide studies, 470

**Books Reviewed**

Antibiotics in Clinical Practice, 356

Biology of Antibiotics - Heidelberg Science Library, 184

Cancer Chemotherapy, 184

Chemotherapy of Malaria and Resistance to Antimalarials, WHO Report, 573

Clinical Pharmacology - Basic Principles in Therapeutics, 354

Dosage Forms and Bioavailability, 571

Drug Interactions, 571

Drugs of Choice 1972-73, 355

Experimental Pharmaceutical Technology, 139

Handbook of Clinical Drug Data, 571

Introduction to Biopharmaceutics, 354

Manual for Pharmacy Technicians, 139

Martindale: The Extra Pharmacopoeia, 138

Medical Writing: The Technic and the Art, 183

The Merck Manual of Diagnosis and Therapy, 138

Organic-Chemical Drugs and Their Synonyms: An International Survey, 183

Pharmacogenetics, WHO Report, 572

Principles of Pathology and Bacteriology, 355

The Psychodynamic Implications of the Physiological Studies of Psychomimetic Drugs, 184

The Psychodynamics of Patient Care, 356

Rx Drug Review, 139

Specifications for Pharmaceutical Preparations, WHO Report, 572

Bosso, John A., Jr. (author) Letter on clinical use of aminophylline, 358; (co-author) Stevens-Johnson Syndrome Associated with Diphenylhydantoin Therapy, 336

Boyd, James R. (author) Letter commenting on Whitney editorial concerning residences, 568

Bretylum Tosylate, myocardial infarction (ab) 364

Briganti, Frank J. (author) Letter asking for broader education, 143

British Pharmaceutical Society, statement on biological availability, 116

BRL 2333, See Amoxicillin

Bronchodilators, aminophylline, 156

Bupivacaine Hydrochloride, evaluation (ab) 363

Buth, J. A. (co-author) A Practical Method of Sterility Monitoring of IV Admixtures and a Method of Implementing a Routine Sterility Monitoring Program, 276

Butler, Thomas H. (author) abstracts, 44, 91, 86, 280, 281; Letter responding to reader comments on Evaluation of IV Filters article, 420; (co-author) Evaluation of Filters in Preventing Contamination in Hyperalimentation Therapy, 317

## C

Cafergot, & propranolol (ab) 323  
Caiola, Stephen M. (co-author) Letter on editorial concerning models for professional practice, 358  
Calcium  
effect of thiazides on serum electrolytes, 503  
spironolactone, use with thiazides, 508  
Calcium Carbonate, hypercalcemia (ab) 425  
Carbenicillin  
decisions as to use (ab) 233  
granulocytopenia (ab) 281  
in renal & hepatic insufficiency, 62  
Cardiac Resuscitation, 234  
Catania, Patrick, N. (author) Letter concerning Dilantin for IV use, 418  
Cawthorne, George Kennedy (co-author) The Pharmacist's Dilemma - Drug Product Selection Using Bioavailability Data, 444  
Cefazolin, & cephaloridine (ab) 238; pharmacodynamics in presence of normal and impaired renal function (ab) 574  
Cephalexin, 252; renal function (ab) 236  
Cephalexin, 252  
Cephaloridine, 252; & cefazolin (ab) 238; therapy in surgical infections (ab) 93  
Cephalosporins, agranulocytosis from (ab) 478; in renal and/or hepatic insufficiency, 252  
Cephalothin, 252; induced anaphylaxis (ab) 361; meningitis (ab) 324  
Chan, N. L. (author) Letter concerning Dilantin for IV use, 419  
Chemotherapy, in tuberculosis (ab) 238  
Chlordiazepoxide, as sedative (ab) 188  
Chloromethyl Methyl Ether, lung cancer (ab) 325  
Chlorpromazine, dissolution characteristics, 408; in acute psychosis (ab) 363; plasma disappearance & cerebral effects (ab) 140  
Cholestyramine Resin, for hyperlipoproteinemia (ab) 45  
Chudzik, Gregory M. (co-author) Stevens-Johnson Syndrome Associated with Diphenylhydantoin Therapy, 336  
Citaneol, See Prilocaine  
Clenocin, See Clindamycin  
Clindamycin, anaerobic infections (ab) 45; colitis (ab) 281; compared with lincomycin (ab) 575; Stevens-Johnson syndrome (ab) 186  
Clinical Pharmacy  
pharmacist as health advisor (ab) 428  
pharmacist's role in cardiopulmonary resuscitation, 298  
scope of education for, 511  
service and education (ed) 5; 58  
Clinical Pharmacy Case Studies  
Amotriptyline Overdose, 451; Barbiturate Intoxication, 309; Heroin Overdose Complicated by Pulmonary Edema, 388; Hypertension with Nephrosclerosis, 208; Metabolic Complications of Hydrochlorothiazide Therapy, 501; Myocardial Infarction Complicated by Arrhythmias, 120; Procainamide-Induced Systemic Lupus Erythematosus, 271; Septic Shock, 25; Stevens-Johnson Syndrome Associated with Diphenylhydantoin, 336  
Clobefrate, acute muscular syndrome (ab) 95  
Clomiphene, in male gonadotrophin deficiency (ab) 325  
Clorazepate Dipotassium, antianxiety agent (ab) 237  
Cloxacillin, in renal & hepatic insufficiency, 62  
Coats, Eugene (author) book review, 184  
Coberly, R. W. (co-author) A Practical Method of Sterility Monitoring of IV Mixtures and a Method of Implementing a Routine Sterility Monitoring Program, 276  
Codino, Rudolph J. (co-author) Factors Involved in Monitoring IV Therapy - A Study of Microbial Growth in IV Fluids, 515  
Cole, Coye M. (co-author) Preparation and Comparison of Technetium-99m Diphosphonate, Polyphosphate and Pyrophosphate as Nuclear Bone Imaging Radiopharmaceuticals, 470  
Colestipol Resin, for hyperlipoproteinemia (ab) 45  
Collagen, vehicle for drug delivery (ab) 575  
Committee on Large Volume Parenterals, Interim Report, 470  
Communication, letters as a means of (ed) 155; networks, physicians', 500  
Compatibility Studies, Intralipid, 351  
Compoz, as sedative (ab) 188  
Conner, Christopher S. (author) Letter on Clinical Pharmacy Case Studies, 143  
Containers, for sterile irrigating solutions, 463

Contamination, in extemporaneous syringe filling, 132; introduction of *P. aeruginosa* into hospitals via vegetables, 566; microbial, of IV solutions, 515, 565; mycelial, in hyperalimentation therapy, 317; of irrigating solutions, 467; of particulate parenterals, 516; of screw-capped bottle system, 463  
Cooper, Robert M. (co-author) The Pharmacist as a Drug Consultant, 58  
Corticosteroid Use, simulated congenital glaucoma (ab) 94  
Cromolyn Sodium, asthma (ab) 91  
Curtis, Elvin G. (co-author) Kinetics of Microbial Growth in Bulk Parenteral Solutions, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177; The Sterility of Screw-Capped Bottle System Containing Irrigating Solution, 463  
Cylacillin, serum and urinary concentrations (ab) 575  
Cyclophosphamide, water intoxication (ab) 425  
Cytoxin, See Cyclophosphamide

## D

Dapsone, peripheral neuropathy (ab) 140  
Darvon, See Propoxyphene  
Davidson, Bobby D. (author) Letter concerning sites of Pharm.D. programs, 192  
Deafness, drug-induced (ab) 325  
Depo-Provera Injections (ab) 282  
Der, Nelson (author) Letter concerning Septic Shock Case Study, 283  
Desipramine, interaction with tranylcypromine (ab) 185  
Desta, B. (co-author) The Dissolution Characteristics of Two Clinically Different Brands of Chlorpromazine HCl Tablets, 408  
Dexamethasone, transient reaction (ab) 142  
Diagnostic Agents  
gallium-67 citrate, 519  
technetium 99m for bone imaging, 470  
Diagnostic Tests, 33  
Diazepam  
aberrant response to (ab) 185  
thrombophlebitis (ab) 186  
Diazoxide  
evaluation, 459  
in hypertensive emergency (ab) 236  
Dicloxacillin, in renal & hepatic insufficiency, 62  
Didier, Edward P. (co-author) The Pharmacist as a Member of the Cardiopulmonary Resuscitation Team, 298  
Digoxin, absorption (ab) 45; bioavailability, 78; dissolution of tablets (ab) 525; equivalence in digoxin levels (ab) 282; in atrial fibrillation (ab) 282; in fetus and infant (ab) 45; and metoprolol (ab) 280; poisoning (ab) 237; and propranolol (ab) 280; therapy (ab) 44  
Dilantin, See Diphenylhydantoin  
Diphenylhydantoin, inhibition of folic acid (ab) 46; irritable bowel syndrome (ab) 188; Stevens-Johnson Syndrome, 336; teratogenicity (ab) 186  
Diphenhydramine, effect on PAS (ab) 422  
Dissolution Characteristics, chlorpromazine HCl tablets, 408  
Disulfiram, interaction with sodium warfarin (ab) 185  
Diuretics, interstitial nephritis (ab) 186  
DMP, meningeal leukemia (ab) 363  
Doriden, See Glutethimide  
Dosage Adjustment, in renal impairment, 382  
Doxycycline, concentrations in seminal fluid (ab) 326  
Drug Abuse  
alcoholism in women (ab) 88  
barbiturate intoxication, 309  
GI's in West Germany (ab) 234  
heroin addiction, 129  
heroin addiction, socioeconomic (ab) 360  
heroin intoxication, treatment, 388  
methadone maintenance program (ab) 234  
methadone programs, naloxone (ab) 282  
narcotic addiction, 100 autopsies (ab) 89  
narcotic addiction, hyperimmunoglobulinemia (ab) 281  
narcotic addiction, surgical complications (ab) 88  
opiate users (ab) 88  
sedatives and suicides, 233  
tranquilizer control (ab) 88  
Drug Actions, Interactions and Reactions, 43, 91, 140, 185, 235, 280, 323, 361, 422, 478, 527, 574  
Drug Activity, determinants, 168  
Drug Addiction, treatment of heroin addiction, 129  
Drug Advertising, comparison in two Finnish medical journals (ab) 360  
Drug Costs, prescribing habits, 492  
Drug Defaulting, by heroin addicts, 129

Drug Delivery System, collagen as a vehicle, 575

Drug Distribution, emergency drugs, 298

Drug Dosage

adjustments in renal impairment, 382  
in renal and hepatic insufficiency, aminoglycosides, 540; cephalosporins, 252; penicillin, 62  
letter regarding cephalothin, 526  
lincomycin and clindamycin in renal impairment (ab) 525

Drug Evaluation Data

diazoxide, 459  
flucytosine, 75  
trichlofos, 126

Drug Information, emergency drugs, 298; pharmacist as drug consultant, 58

Drug Intelligence & Clinical Pharmacy, Statement of Ownership, Management & Circulation, 528

Drug Interactions

acetaminophen, immune thrombocytopenia (ab) 45  
aminophylline, 156  
anesthetics, local (ab) 93  
anticonvulsants, folic acid & epilepsy (ab) 422  
ascorbic acid, glucose levels (ab) 323  
ascorbic acid, warfarin (ab) 46  
benzhexol, fluphenazine therapy (ab) 93  
benzodiazepines, warfarin (ab) 93  
cafergot-propranolol (ab) 323  
desipramine, tranylcypromine toxicity (ab) 185  
digoxin-metoprolol (ab) 280  
digoxin-propranolol (ab) 280  
diphenhydramine-PAS (ab) 422  
diphenylhydantoin, folic acid (ab) 46  
disulfiram, warfarin (ab) 185  
fluphenazine therapy, benzhexol (ab) 93  
folic acid, anticonvulsants & epilepsy (ab) 422  
folic acid, diphenylhydantoin (ab) 46  
gentamicin-penicillin (ab) 323  
hepatic drug metabolism, 263  
hypoproteinememia-trichlofos (ab) 235  
immune thrombocytopenia, acetaminophen (ab) 45  
insulin, propranolol (ab) 94  
levodopa-methylodopa (ab) 323  
levodopa-MK-486, decarboxylase inhibition (ab) 364  
methylodopa-levodopa (ab) 323  
metoprolol-digoxin (ab) 280  
metyrapone test, 33  
MK-486-levodopa, decarboxylase inhibition (ab) 364  
neuroleptics, tricyclic antidepressants (ab) 93  
PAS-diphenhydramine (ab) 422  
penicillin-gentamicin (ab) 323  
propranolol-digoxin (ab) 280  
propranolol-cafergot (ab) 323  
propranolol, insulin (ab) 94  
serum glucose-ascorbic acid (ab) 323  
steroids, gastrointestinal complications (ab) 280  
streptomycin-vancomycin (ab) 235  
tranylcypromine, desipramine toxicity (ab) 185  
trichlofos-hypoproteinememia (ab) 235  
tricyclic antidepressants, neuroleptics (ab) 93  
vancomycin-streptomycin (ab) 235  
warfarin, ascorbic acid (ab) 46  
warfarin, benzodiazepines (ab) 93  
warfarin, disulfiram (ab) 185  
Drug Metabolism, hepatic inhibition, 263  
Drug Procurement, pharmacist's dilemma in using bioavailability data, 444  
Drug Product Selection  
pharmacist's dilemma in using bioavailability data, 444; (ed) 443  
physicians' prescribing habits, 492; 557  
Drug Therapy, See also Clinical Pharmacy Case Studies  
aminoglycosides, in renal & hepatic insufficiency, 540  
amitriptyline overdose, 451  
amoxillin in urinary tract infections (ab) 576  
anaphylactic shock and anaphylactoid reaction, 394  
anticoagulant therapy in myocardial infarction, 202  
arrhythmias, 271  
barbiturate intoxication, 309  
bioavailability factors, 168  
cardiopulmonary resuscitation, 298  
cephalosporins, in renal and/or hepatic insufficiency, 252  
contamination in hyperalimentation therapy, 317  
convulsions, drug-induced (ab) 46  
deafness, drug-induced (ab) 325  
diphenylhydantoin therapy, 336  
dosage regimen adjustments in renal impairment, 382  
drugs for cardiopulmonary arrest (letter) 570  
factors that modify, 346  
gallium-67 citrate, 519  
gonorrhea, 205  
heroin intoxication, 388

hyperalimentation review, 413  
hypertension, 208; (ab) 525  
levodopa therapy, obstacles to (ab) 89  
measles vaccination, neurologic disorders (ab) 281  
metabolic complications of hydrochlorothiazide therapy  
methadone program, 129  
myocardial infarction, 120  
parenteral, 515  
penicillins, in renal & hepatic insufficiency, 62  
phenothiazine in psychosis (ab) 526  
prescribing habits of physicians, 492, 557  
renal impairment, dosage adjustments, 382  
septic shock, 25  
sterility, drug-induced (ab) 281  
technetium-99m salts for bone imaging, 470  
theophylline, IV doses (ab) 566  
**Drug Toxicity**, See also Adverse Drug Reactions  
amitriptyline overdose, 451  
barbiturate overdose, 309  
heroin overdose, 129, 388  
hydrochlorothiazide, 501  
**Drugs**, adverse reactions in children, 106  
**Dryps, John S.** (co-author) Hyperalimentation Review, 413  
**Duck Embryo Rabies Vaccine**, adverse reactions (ab) 324  
**Dunson, George L.** (co-author) Preparation and Comparison of Technetium-99m Diphosphate, Polyphosphate and Pyrophosphate as Nuclear Bone Imaging Radiopharmaceuticals, 470

## E

**Eckel, Fred M.** (co-author) The Pharmacist's Dilemma - Drug Product Selection Using Bioavailability Data, 444; Sterility Monitoring of IV Admixtures, 276; Letter on editorial concerning models for professional practice, 358  
**Editing**, some principles, 340  
**Editorial by H. A. K. Whitney, Jr.**  
Residency Programs - Training Pharmacists for Hospitals, 335  
**Editorials by Donald E. Francke**  
An Open University for Continuing Education, 539  
Bioavailability Statements, 105  
Clinical Pharmacy Service and Education: IV. Objectives of Hospital-Based Internships and the Role of Colleges of Pharmacy, 5  
Clinical Pharmacy Service and Education: V. Hospital-Based Residency Programs Redefining the Pharmacist, 57  
Establishing a Model for Clinical Practitioners, 251  
Letters as a Means of Communication, 155  
Models for Professional Practitioners, 201  
Objectives of Pharmacy Residency Programs, 297  
Prescribing Habits of Physicians, 491  
Selection of Residents, 381  
The Pharmacist's Dilemma - Drug Product Selection Using Bioavailability Data, 443  
**Education, Pharmaceutical**  
clinical excellence, 569  
continuing education (ed) 539  
objectives of residency programs (ed) 297  
open university (ed) 539  
Pharm.D. degree (letter) 568  
pharmacist as clinical model (ed) 251  
pharmacist as professional model (ed) 201  
pharmacy residency programs (ed) 335  
scope of clinical pharmacy, 511  
selection of residents (ed) 381  
**Elavil**, See Amitriptyline  
**Erythromycin Estolate**, biliary colic (ab) 141  
**Eshelman, Fred** (author) abstracts, 94, 186, 187, 281, 324, 326, 478  
**Extemporaneous Syringe Filling**, degree of contamination, 132

## F

**Ferrous Sulfate**, adverse drug reactions (ab) 324  
**Filters**, in preventing mycelial contamination in hyperalimentation therapy, 317  
**Finger, Kenneth F.** (co-author) Effectiveness of a Three Month Methadone Program, 129  
**Fitzpatrick, William A.** (author) Letter on Kappa Psi Pharmaceutical Fraternity, 144  
**Flores, L. L.** (author) Growth of Microorganisms in Parenteral Nutritional Fluids, 226  
**Flucytosine**, evaluation, 75  
**Fluoramar**, See Fluoxetine  
**Fluothane**, See Halothane  
**Fluphenazine**, in acute psychosis (ab) 363; interaction with benzhexol (ab) 93  
**Fluoxetine Anesthesia**, jaundice (ab) 141  
**Folic Acid**, anticonvulsants, and epilepsy (ab) 422; inhibition by diphenylhydantoin (ab) 46  
**Francke, Donald E.** (author) book review, 139;

editorials: An Open University for Continuing Education, 539; Bioavailability Statements, 105; Clinical Pharmacy Service and Education: IV. Objectives of Hospital-Based Internships and the Role of Colleges of Pharmacy, 5; V. Hospital-Based Residency Programs - Redefining the Pharmacist, 57; Establishing a Model for Clinical Practitioners, 251; Letters as a Means of Communication, 155; Models for Professional Practitioners, 201; Objectives of Pharmacy Residency Programs, 297; The Pharmacist's Dilemma, Drug Product Selection Using Bioavailability Data, 443; Prescribing Habits of Physicians, 491; Selection of Residents, 381  
**Frank, John T.** (author) Barbiturate Intoxication, 309; Intralipid Compatibility Study, 351; Septic Shock, 25; letter on Dilantin incompatibility, 287; letter responding to comments on creatinine serum levels, 421; letter responding to comments on Dilantin for IV use, 419; letter responding to comments on septic shock case study, 283  
**Fratkin, Melvin J.** (co-author) Gallium-67 Citrate - A Review of Its Properties and Current Status in Physical Medicine, 519  
**Frazier, Walter M.** (author) book review, 139  
**Friedman, A.** (author) Letter on Amesec, 327  
**Furosemide**, effects in congestive heart failure (ab) 363; ventilatory response to CO<sub>2</sub> (ab) 44

## G

**Gallamine Triethiodide**, hazards of retention (ab) 141  
**Gallium-67 Citrate**, status in nuclear medicine, 519  
**Gebo, Homer** (author) Letter requesting definition of half-life of drug, 357  
**Geiwitz, Allen R.** (author) Letter praising Clinical Pharmacy Case Studies, 421  
**Generic Prescribing**, prescribing habits of physicians, 492  
**Gentamicin** and penicillin in enterococcal infections (ab) 323; in neonates & infants (ab) 140; pharmacokinetics (ab) 362  
**Gibson, J. Tyrone** (author) Letter about term "Clinical Pharmacy," 143  
**Giusti, Donald L.** (author) Clinical Use of Antimicrobial Agents in Patients with Renal and Hepatic Insufficiency: Aminoglycosides, 540; Cephalosporins, 252; Penicillin, 62; letter concerning cephalothin dosage in renal impairment, 526; book reviews, 354, 356; (co-author) Dosage Regimen Adjustments in Renal Impairment, 382  
**Glutethimide**, osteomalacia (ab) 362  
**Goicoechea, Frank J.** (author) Myocardial Infarction Complicated by Arrhythmias, 120; Procainamide-Induced Systemic Lupus Erythematosus, 271  
**Gonik, Morris** (co-author) Kinetics of Microbial Growth in Bulk Parenteral Solutions, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177  
**Gonorrhea**, antibiotics in, 205  
**Greenwood, R.** (author) abstracts, 91  
**Guanethidine**, therapy in hypertension (ab) 525

## H

**Half-Lives**, See also Pharmacokinetics  
cefazolin (ab) 574  
cephalothin (Letters) 526  
clindamycin (ab) 526  
cephalosporin, 252  
diazoxide, 461  
digoxin poisoning, 237  
lincomycin (ab) 526  
**Haloprogyn**, clinical efficacy of (ab) 187; for dermatophyte infections (ab) 188  
**Halothane**, lymphocyte function tests (ab) 141  
**Hayton, William L.** (co-author) Dosage Regimen Adjustments in Renal Impairment, 382  
**Health Care Delivery**, effects of prescription charges (ab) 233  
**Health Care Sociology**, 88, 232, 360, 428  
**Helling, Dennis K.** (author) abstracts, 236, 237  
**Hemolysis**, drugs and chemicals, 6  
**Hemolytic Anemia**, 6  
**Hendele, Leslie** (author) Uncomplicated Gonococcal Infections, 205  
**Heparin**, activity of two different preparations (ab) 92; monitoring treatment (ab) 45; therapy in myocardial infarction, 202; venous thrombosis (ab) 282  
**Hepatic Drug Metabolism**, drug interactions, 263  
**Heroin**, socioeconomics of addiction (ab) 360; treatment of intoxication, 388  
**Hetacillin**, in renal & hepatic insufficiency, 62  
**Hiatt, Robert A.** (author) Heroin Overdose Complicated by Pulmonary Edema, 388  
**Hirsch, Jerry I.** (co-author) Gallium-67 Citrate

- A Review of Its Properties and Current Status in Nuclear Medicine, 519  
**Ho, Norman F. H.** (co-author) Kinetics of Microbial Growth in Bulk Parenteral Solutions, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177; The Sterility of Screw-Capped Bottle System Containing Irrigating Solution, 463  
**Hoar, Marion E.** (author) Extemporaneous Syringe Filling and Degree of Contamination, 132  
**Hoffmann, Richard P.** (co-author) Hyperalimentation Review, 413; (author) Letter concerning clinical excellence, 569  
**Hosain, Fazle** (co-author) Preparation and Comparison of Technetium-99m Diphosphate, Polyphosphate and Pyrophosphate as Nuclear Bone Imaging Radiopharmaceuticals, 470  
**Hospital Pharmacist**, role (ab) 360  
**Hu, Ada** (author) abstracts, 325, 326  
**Hydralazine**, therapy in hypertension (ab) 525  
**Hydrochlorothiazide**, pneumonitis (ab) 281; metabolic complications of therapy, 501  
**Hyperalimentation**, See Parenteral Hyperalimentation  
**Hyperimmunoglobulinemia**, narcotic addiction (ab) 281  
**Hyperstat**, See Diazoxide  
**Hypertension**, with nephrosclerosis, 208  
**Hypoprothrombinemia**, and triclofos (ab) 235

## I

**Imuran**, See Azathioprine  
**Inderal**, See Propranolol  
**Insulin**, with propranolol (ab) 94  
**Intralipid**, compatibility studies, 351  
**Ipecac**, in poisonings (ab) 326  
**Iron**, allergic dermatitis from (ab) 422; sarcoma (ab) 423  
**Irrigating Solutions**, sterility in screw-capped bottles, 463  
**Isenberg, Henry D.** (author) The Ecology of Nosocomial Disease, 352  
**Isoniazid**, hepatitis from (ab) 479  
**I.V. Additive Reviews**, See also Letters concerning IV reviews  
Evaluation of Filters in Preventing Mycelial Contamination in Hyperalimentation Therapy, 317  
**Extemporaneous Syringe Filling**, Degree of Contamination, 132  
**Growth of Microorganisms in Parenteral Nutritional Fluids**, 226  
**Guidelines for the Administration of Commonly Used Intravenous Drugs**, 38  
**Hyperalimentation Review**, 413  
**Intralipid Compatibility Study**, 351  
**Introduction of *P. aeruginosa* into a Hospital Via Vegetables** (ab) 567  
**IV Additive Guidelines** (ab) 566  
**Kinetics of Microbial Growth in Bulk Parenteral Solutions**, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177  
**Microbial Contamination of Infusion Fluids** Arising from Drug Additions Administration (ab) 565  
**Monitoring Microbial Growth**, 515  
**National Coordinating Committee on Large Volume Parenterals**, 475  
**Policy and Procedure Manual**, 84  
**Sterility Monitoring of IV Admixtures**, 276  
**The Ecology of Nosocomial Disease**, 352  
**Theophylline**, rational IV dose, 567  
**Why an IV Additive Service** (ab) 567

## J

**Jones, M.** (author) abstracts, 46, 280  
**Journals**, style, presentation and illustration, 340

## K

**Kafocin**, See Cephaloglycin  
**Kampa, Ingo S.** (co-author) Diagnostic Value of 17-Hydroxycorticosteroids Urinary Levels as Indication of Pituitary Function During the Metrapone Test, 33  
**Kandzer, P.** (author) abstracts, 43, 46, 325  
**Kato, Donald B.** (author) Letter concerning "out-of-field" subscriptions to *Postgraduate Medicine*, 359  
**Keflex**, See Cephalixin  
**Kellick, Kenneth A.** (co-author) Letter concerning Dilantin for IV use, 418  
**Kerege, John** (co-author) Guidelines for the Administration of Commonly Used Intravenous Drugs, 38  
**Knapp, Gene** (co-author) Letter on digoxin tablet bioavailability, 286  
**Koup, Jeffrey R.** (author) Letter concerning the history of clinical pharmacy, 191



# L

**Laboratory Test Values, 33**  
**Large Volume Parenterals, report on National Coordinating Committee, 475**  
**Letters to the Editor**  
 adverse drug reactions in children, comments and author's response, 327  
 Amesec contains aminophylline, 327  
 aminophylline, comment on clinical use, 358  
 cephalothin dosage in renal insufficiency, 526  
 clinical excellence, 568  
 Clinical Pharmacy Case Studies, praise for, 143, 421  
 clinical pharmacy in 18th century Italy (ab) 191  
 clinical practitioners as models, comment on editorial, 359  
 creatinine serum levels, comments and author's response, 420  
 digoxin, bioavailability, 286  
 digoxin, comment on dosage, 191  
 Dilantin for IV use, comments and author's response, 418, 419  
 Dilantin incompatibility, 287  
**Drug Intelligence & Clinical Pharmacy**, praise for, 359  
 evaluation of IV filters, comments and author's response, 419  
 half-life of drug, request for definition and Dr. Wagner's definition, 357  
 IV filters, 568  
 IV guidelines, comments, 287, 326, 568 and author's response, 327, 569  
 Kappa Psi Pharmaceutical Fraternity, 144  
 plea for broader education, 143  
 professional practitioners as models, comment on editorial, 358  
 residency programs — training pharmacists, 568  
 septic shock article, comments and author's response, 283  
 sites of Pharm.D. programs, 192  
 subscriptions "out-of-field," 359  
 use of term "clinical pharmacy," comment on editorial and author's response, 143  
 value of *International Pharmaceutical Abstracts*, 527  
**Levodopa**, long term therapy, start hesitation (ab) 361; metabolic response (ab) 46; & methyldopa (ab) 323; & MK-486, decarboxylase inhibition (ab) 364; sociopsychological obstacles to therapy (ab) 89; use in 243 patients (ab) 187  
**Lidocaine**, sinus standstill (ab) 187  
**Lincocin**, See *Lincomycin*  
**Lincomycin**, anaerobic infections (ab) 45; compared with clindamycin (ab) 575  
**Literature**, 138, 183, 354  
**Lithium Carbonate**, a clinic (ab) 233; acute brain syndrome (ab) 141; in intractable depressions (ab) 44; in pregnancy (ab) 422; myocardial irritability (ab) 95  
**Longshaw, Rodney N.** (author) Inhibition of Hepatic Drug Metabolism, 263  
**Lorazepam**, visual function (ab) 427  
**Loridine**, See *Cephalexin*  
**LSD users**, reproductive detriment (ab) 142

# M

**MacFarlane, M. David** (co-author) Anaphylactic Shock and Anaphylactoid Reaction, 394  
**Mann, Kingsley** (co-author) Factors that Modify Drug Activity and Patient Response, 346  
**Manpower**, allied health (ab) 234  
**Martens, Phyllis J.** (co-author) Kinetics of Microbial Growth in Bulk Parenteral Solutions, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177  
**Martinot, Pierre** (author) The Essence of a Professional Journal, 340  
**Matulane**, See *Procaine*  
**Measles Vaccination**, adverse reactions (ab) 281  
**Meister, Fred L.** (author) Hypertension with Nephrosclerosis, 208  
**Mellari, See Thioridazine**  
**Mellor, Marilyn K.** (co-author) Preparation and Comparison of Technetium-99m Diphosphonate, Polyphosphate and Pyrophosphate as Nuclear Bone Imaging Radiopharmaceuticals, 470  
**Metabolic Alkalosis**, 507  
**Metabolic Complications of Hydrochlorothiazide Therapy**, 501  
**Methadone**, naloxone in diagnosis of addiction (ab) 282; programs, 234; in heroin addiction, 129  
**Methicillin**, in renal & hepatic insufficiency, 62  
**Methimazole**, jaundice (ab) 235  
**Methotrexate**, in Mucha-Haberman Disease (ab) 92; in pemphigus vulgaris (ab) 92  
**Methoxyflurane**, renal failure (ab) 236  
**Methyldopa**, hepatitis (ab) 362; therapy in hypertension (ab) 525; and levodopa (ab) 323

**Methylglucamine Iothalamate**, hyperosmolality (ab) 142  
**Metoclopramide**, digoxin (ab) 280  
**Metypapone Test**, drug interactions, 33  
**Microbial Growth**, in parenteral solutions, 177; 516; See also IV additives  
**Miller, Russell R.** (author) Prescribing Habits of Physicians — A Review of Studies on Prescribing of Drugs, Parts I-III, 492; Parts IV-VI, 557  
**Mitotane**, in carcinoma (ab) 237  
**MK-486**, and levodopa, decarboxylase inhibition (ab) 364  
**Moore, Robert C.** (co-author) Effectiveness of a Three Month Methadone Program, 129  
**Morphine**, compared to propiram (ab) 187; hemodynamics (ab) 43  
**Munzenberger, Paul** (author) Letter on adverse drug reactions in children article, 327  
**Myocardial Infarction**, anticoagulant therapy, 202; case study, 120

# Mc

**McCarron, Margaret M.** (editor) *Clinical Pharmacy Studies*, 25, 120, 208, 271, 309, 336, 388, 394, 451, 501; (co-author) Anaphylactic Shock and Anaphylactoid Reaction, 394  
**McCollum, Nathan** (author) Drug Evaluation Data: Flucytosine, 75  
**McLeod, Don C.** (editor) Drug Evaluation Data, 75, 126, 459; (co-author) Diazoxide; (author) abstracts, 43, 44

# N

**Nafcillin**, in renal & hepatic insufficiency, 62; nephritis from (ab) 479  
**Naloxone**, in methadone programs (ab) 282  
**Narcotic Addiction**, 100 autopsies (ab) 89; hyperimmunoglobulinemia (ab) 281; surgical complications (ab) 88  
**Narcotic Analgesics**, undertreatment with (ab) 364  
**Neuroleptics**, interaction with tricyclic antidepressants (ab) 93  
**New Drugs**, prescribing habits of physicians, 492  
**Nickel Sensitivity**, asthma (ab) 423  
**Nosocomial Disease**, ecology, 352

# O

**O'Brien, Donna** (author) Letter praising IV guidelines article, 287  
**Oncovin**, See *Vincristine*  
**Opiate Users** (ab) 88  
**Oral Contraceptives**, adverse reactions (ab) 425; blood pressure (ab) 94; breast lesions (ab) 324; hemolytic uremic syndrome (ab) 425  
**Oxacillin**, in renal & hepatic insufficiency, 62

# P

**Pagones, J. N.** (author) Growth of Microorganisms in Parenteral Nutritional Fluids, 226  
**Palmer, Henry A.** (co-author) Factors Involved in Monitoring IV Therapy — A Study of Microbial Growth in IV Fluids, 515  
**Pancuronium** (ab) 238; in children (ab) 427  
**Parenteral Hyperalimentation**, a review, 413; microbial growth in solutions, 177, 226; mycelial contamination, 317  
**Parenteral Solutions**, See also IV Additives; filters, 517; monitoring microbial growth, 515; microbial growth, 177, 226; mycelial contamination, 317; Report of National Coordinating Committee on, 475  
**Particulate Matter**, committee on, 516  
**PAS**, inhibition by diphenhydramine (ab) 422  
**Patel, Jayant A.** (co-author) Kinetics of Microbial Growth in Bulk Parenteral Solutions, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177; The Sterility of Screw-Capped Bottle System Containing Irrigating Solution, 463  
**Patient**, response to drug therapy and pharmacist's role with patient records, 346  
**Pediatric Pharmacy**, adverse drug reactions, 106; case study, 336  
**Pediatrics**, patient care effectiveness (ab) 90  
**Pelso, Francis R.** (author) abstracts, 93, 238  
**Penicillin**, arrest of mature bone marrow elements (ab) 325; choice of penicillinase-resistant (ab) 92; for streptococcal pharyngitis (ab) 44; in enterococcal infections (ab) 323; in renal and hepatic insufficiency, 62; in venereal disease (ab) 280; induced anaphylaxis (ab) 361  
**Pentazocine**, hemodynamics (ab) 43  
**Penthrane**, See *Methoxyflurane*  
**Pentylentetrazol**, efficacy (ab) 91

**Pernarowski, M.** (co-author) The Dissolution Characteristics of Two Clinically Different Brands of Chlorpromazine HCl Tablets, 408  
**Pharmaceutical Society of Great Britain**, statement on biological availability, 116  
**Pharmacist**, See also Clinical Pharmacy; as drug consultant, 58; as health advisor (ab) 428; as a model in education (ed) 201, 251; role on cardiopulmonary resuscitation team, 298; role in preventing allergic reactions, 394; role in patient records, 346  
**Pharmacokinetics**, See also Biopharmaceutics and Half-Lives; antibiotics, 62; cefazolin, 574; cephalosporins, 252; cefazolin, 575; gentamicin, 542; kanamycin, 545; neomycin, 548; streptomycin, 549; tobramycin (ab) 362; dosage adjustment in renal impairment, 382  
**Pharmacy**, image (ab) 232; professionalism (ed) 201; residency programs (ed) 297, 335; See also Clinical Pharmacy and Editorials  
**Pharmatips**, for emergency drugs, 298  
**Phencyclidine induced psychosis** (ab) 574  
**Phenothiazine**, in acute psychosis (ab) 363, 526  
**Physicians**, number required for primary care (ab) 89; prescribing habits of, 492, 557  
**Piccoro, John J., Jr.** (co-author) Guidelines for the Administration of Commonly Used Intravenous Drugs, 38  
**Pierpaoli, Paul G.** (co-author) Factors Involved in Monitoring IV Therapy — A Study of Microbial Growth in IV Fluids, 515  
**Pitlick, William H.** (co-author) Scope of Clinical Pharmacy Education, 511  
**Pituitary Function**, 33  
**Plein, Elmer M.** (co-author) Scope of Clinical Pharmacy Education, 511  
**Pluhar, Robert E.** (co-author) Evaluation of Filters in Preventing Contamination in Hyperalimentation Therapy, 317; abstracts, 235  
**Podophyllum** (ab) 235  
**Porter, L. Kent** (author) Letter concerning digoxin dosage, 191  
**Potassium**, effect of thiazides on serum electrolytes, 503; glucose, 508  
**Potassium Supplements**, long-term diuretics (ab) 43  
**Prednisone**, acute reactions (ab) 95; dosage (ab) 235; extrapyramidal symptoms (ab) 324; in pemphigus vulgaris (ab) 92  
**Prescribing Habits of Physicians**, A Review of Studies on Prescribing of Drugs, Parts I-III, 492; Parts IV-VI, 557  
**Prilocaine**, methemoglobinemia (ab) 94  
**Prince, Randall A.** (author) Anticoagulation Therapy in Myocardial Infarction, 202  
**Procainamide** in Arrhythmias, 271  
**Procaine**, allergic reaction (ab) 95  
**Professionalism**, pharmacy, 58; (ed) 201  
**Propanteline**, & digoxin (ab) 187  
**Propiram**, compared to morphine (ab) 187  
**Propoxyphene** (ab) 236  
**Propranolol**, agranulocytosis (ab) 281; & cafergot (ab) 323; influence on insulin (ab) 94  
**Propylthiouracil**, hypoprothrombinemia (ab) 142  
**Prostaglandin F<sub>2α</sub>**, during early pregnancy (ab) 325  
**Pseudomonas aeruginosa**, introduction via vegetables into hospitals (ab) 566  
**Purchasing of Drugs**, 444

# R

**Rabies Vaccine**, adverse reactions (ab) 324  
**Radiopharmaceuticals**, gallium-67 citrate, 519  
 technetium-99m diphosphonate, polyphosphate and pyrophosphate for bone imaging, 470  
**Rapp, Robert P.** (co-author) Guidelines for the Administration of Commonly Used Intravenous Drugs, 38; Letters replying to comments on IV Guidelines article, 327, 569; Letter commenting on article on Evaluation of IV Filters, 419  
**Rauwolfia**, therapy in hypertension (ab) 525  
**Reaction**, anaphylactic shock, 394  
**Renal Function**, evaluation of renal and tubular function, 208; dosage adjustments in impaired, 382; drug usage in impaired (ab) 188; penicillin in impaired, 62; cephalosporins in impaired, 252; aminoglycosides in impaired, 540  
**Reserpine**, therapy in hypertension (ab) 525  
**Residency Programs**, letter regarding editorial, 527; See also editorials  
**Rifadin**, See *Rifampicin*  
**Rifampicin**, hemolysis (ab) 423  
**Rifampin**, See *Rifampicin*  
**Rimactane**, See *Rifampicin*  
**Ritschel, Gerda** (author) book review, 184, 355  
**Ritschel, W. A.** (author) book review, 139, 354  
**Rosenberg, Jack M.** (co-author) Diagnostic Value of 17-Hydroxycorticosteroids Urinary Levels as Indication of Pituitary Function During the Metypapone Test, 33; Factors That Modify Drug Activity and Patient Response, 346  
**Rubin, Peter E.** (co-author) Effectiveness of a

Three Month Methadone Program, 129  
 Ruskin, Arthur (author) Letter on digoxin bioavailability, 286

## S

Sachtler, Gary (author) Letter concerning Dilantin for IV use, 418  
 Salicylates, accumulation kinetics (ab) 43; adverse drug reactions (ab) 324  
 Schulze, Bernd W. (author) Metabolic Complications of Hydrochlorothiazide Therapy, case study, 501  
 Schurig, John E., Jr. (author) Letters commenting on IV Guidelines article, 326, 568  
 Schwartz, Neal (co-author) The Pharmacist as a Member of the Cardiopulmonary Resuscitation Team, 298  
 Schwerman, Earl (co-author) The Pharmacist as a Member of the Cardiopulmonary Resuscitation Team, 298  
 Sedatives, & suicides, 233  
 Sernylan, See Phencyclidine  
 Serum Glucose Values, ascorbic acid (ab) 323  
 Sharpe, Jr., Alton R. (co-author) Gallium-67 Citrate - A Review of Its Properties and Current Status in Nuclear Medicine, 519  
 Shetter, Eli (co-author) The Pharmacist as a Drug Consultant, 58  
 Shock, treatment of septic, 25  
 Singletary, James R., Jr. (author) abstracts, 93, 185, 187, 237, 238  
 Siskin, Stewart B. (author) letter concerning creatinine serum levels, 420  
 Skaggs, Charles O. (author) letter praising DICP, 359  
 Skelly, Jerome P. (co-author) letter on digoxin tablet bioavailability, 286  
 Sleasman, W. (author) abstracts, 92  
 Smith, Dorothy L. (author) abstracts, 91, 92, 93, 94, 185, 188, 363, 427, 525  
 Smith, R. (author) abstracts, 46  
 Sociology, pharmacy, 58, See also Health Care Sociology  
 Socrates on Clinical Excellence, 569  
 Sodium, effect of thiazides on serum electrolytes, 502  
 Sorby, Donald L. (co-author) Evaluation of Biologic Availability of Digoxin from Tablets, 78  
 Spatz, Marvin (co-author) The Sterility of Screw-Capped Bottle System Containing Irrigating Solution, 463  
 Steckel, Steven D. (co-author) Kinetics of Microbial Growth in Bulk Parenteral Solutions, I. *S. faecalis* and *B. subtilis* in Dextrose-Saline and Hyperalimentation Solutions, 177  
 Stelazine, See Trifluoperazine  
 Sterility, of commercially available irrigating solutions, 463  
 Sterility Monitoring, IV admixtures, 276, 515; See also IV additives  
 Sterilization, of irrigating solutions in screw-capped containers, 463  
 Steroids, gastrointestinal complications (ab) 280  
 Stevens-Johnson Syndrome, and diphenylhydantoin therapy, 336  
 Stevenson, John S. (co-author) Preparation and Comparison of Technetium-99m Diphosphate, Polyphosphate and Pyrophosphate as Nuclear Bone Imaging Radiopharmaceuticals, 470  
 Streptomycin, & vancomycin in enterococcal endocarditis (ab) 235  
 Swanson, Margo (author) Drugs, Chemicals and Hemolysis, 6  
 Systemic Lupus Erythematosus, 271

## T

Tapazole, See Methimazole  
 Tatro, Davis S. (author) Adverse Drug Reactions in Children, 106; letter in response to comments on adverse drug reactions in children article, 327  
 Technetium-99m, preparation and comparison of the diphosphate, polyphosphate, and pyrophosphate as nuclear bone imaging radiopharmaceuticals, 470  
 Thayer, C. (author) abstracts, 280

Theophylline, review of clinical use, 156; IV dose, 567  
 Thiazides, Metabolic complications of therapy, 501; therapy in hypertension (ab) 525  
 Thioridazine, agranulocytosis and hepatitis (ab) 325  
 Thompson, Conrad O. (co-author) The Pharmacist as a Member of the Cardiopulmonary Resuscitation Team, 298  
 Thompson, Gregory A. (author) Amitriptyline Overdose, 451; letter of correction, 570  
 Tobias, Dianne C. (co-author) letter concerning Dilantin for IV use, 418  
 Tobramycin, comparative pharmacokinetics (ab) 362  
 Tong, Theodore G. (author) Aminophylline - Review of Clinical Use, 156  
 Tonnies, Fred (author) letter commenting on editorial concerning models for clinical practitioners, 359  
 Toxicity, amitriptyline overdose, 451; antibiotics, 62; barbiturates, 309; heroin, 388  
 Tozer, Thomas N. (co-author) Evaluation of Biologic Availability of Digoxin from Tablets, 78  
 Tranlycypromine, interaction with desipramine (ab) 185; in intractable depressions (ab) 44  
 Triclosan, and hypoprothrombinemia (ab) 235; evaluation of, 126  
 Tricyclic Antidepressants, interaction with neuroleptics (ab) 93  
 Trifluoperazine, extrapyramidal symptoms (ab) 324

## U

Unipen, See Nafcillin  
 Uric Acid, effect of thiazides on serum electrolytes, 504  
 Urinary Tract Infections, 25

## V

Valium, See Diazepam  
 Vancomycin, & streptomycin in enterococcal endocarditis (ab) 235  
 Varano, Carmine (author) letter on value of *International Pharmaceutical Abstracts*, 526  
 Vehicle, collagen as vehicle for eye drops, 575  
 Vincristine, seizures with (ab) 478  
 Vitamin A, topical, in psoriasis (ab) 427  
 Vitamin A Acid, in palmoplantar keratoderma (ab) 188

## W

Wagner, John G. (author) Biologic Availability, Determinant Factor of Therapeutic Activity of Drug, 168; letter defining half-life of drug, 357  
 Warfarin, ascorbic acid (ab) 46; interactions with benzodiazepines (ab) 93; interaction with disulfiram (ab) 183  
 Water, effect of thiazides on serum electrolytes, 505  
 Wertheimer, Albert I. (co-author) The Pharmacist as a Drug Consultant, 58  
 Whitney, Harvey A. K., Jr. (author) Letter responding to reader comments on prior editorial, 143; (ed) Residency Programs - Training Pharmacists for Hospitals, 335; book reviews, 138, 183, 355, 356  
 Wilkinson, W. R. (author) Growth of Microorganisms in Parenteral Nutritional Fluids, 226  
 Writing For Publication, 340

## X-Y-Z

Xylocaine, See Lidocaine  
 Zost, Edward D. (author) Letter commenting on article concerning IV filters, 568

## ADVERTISERS

American Society of Hospital Pharmacists  
*International Pharmaceutical Abstracts*,  
 Ap-149, Ma-196  
 IPA Information Systems, Jl-322, S-426  
 Voices 12/60, Ja-IBC  
 Drug Intelligence & Clinical Pharmacy, Inc.  
*Drug Intelligence & Clinical Pharmacy*,  
 S-432, D-578  
 Drug Intelligence Publications  
 Biopharmaceutics and Relevant Pharmacokinetics, F-IBC, Mr-IBC, Ap-IBC, Ma-IBC, Ju-IBC, Ag-IBC, S-IBC, O-IBC, N-IBC  
 Handbook of Clinical Drug Data, Ju-285, Jl-321, Ag-334, S-378, O-442, N-490, D-IBC  
 Handbook of Drug Interactions, F-54, D-533  
 Handbook of IV Additive Reviews, F-77  
 Index Nominum, D-537  
 Organic Medicaments and Their Synonyms, Ju-284, S-380, D-584  
 Perspectives in Clinical Pharmacy, Ja-4, F-56, Mr-104, Ap-189, Ma-239, Ju-250, Jl-321, Ag-331, S-IFC, O-IBC, N-485, D-584  
 Publications Available, Ja-IFC, F-IFC, Mr-IFC, Ap-IFC, Ma-IFC, Ju-IFC, Jl-IFC, Ag-IFC, S-379, D-IFC  
 Billings Deaconess Hospital  
 Chief Pharmacist Needed, Ag-365  
 Bristol Laboratories  
 Bristoject Medication System, Jl-295  
 Ciba-Geigy, Inc.  
 DBI-TD, N-483; D-536  
 Paul de Haen, Inc.  
 Drug Information Systems, Ja-47, F-95, Ap-148, Ju-245, Jl-293, S-375, O-439  
 Elkins-Sinn, Inc.  
 Dosette Hospital Products, Ja-OBC, F-OBC, Mr-OBC  
 Dosette Single Dose Vials, Ap-OBC  
 Hollister, Inc.  
 Hollister Product Parade, Ju-243  
 inPHARMation  
 Top 200 Drugs, Ju-287, Ag-333  
 Eli Lilly and Company  
 Identidose, Jl-IBC, Ag-OBC, S-371, D-OBC  
 Keflin IV, Ja-3, Ap-150, Ma-200, Ju-OBC, O-OBC, N-486  
 New Packaging Concept, F-52, Mr-100  
 J. B. Lippincott Company  
 New Pharmacy and Pharmacology Texts, Ma-225  
 McGraw Laboratories, Inc.  
 FreAmine, Ju-244, 245, Jl-292, 293, Ag-332, 333, S-374, 375, O-438, 439  
 Plenum Publishing Corporation  
 Journal of Pharmacokinetics and Biopharmaceutics, Mr-102, Jl-294, S-424, O-435, N-484, D-532  
 Rachelle Laboratories  
 Bookshelf Selections, Winter 1973, Ja-47; Spring 1973, Ap-148; Doxychel, D-538  
 Roche Laboratories  
 Announcement of 1973 Roche Research Program, F-53, Mr-103, Ap-151, Ma-197  
 Dalmane, Ma-198, 199, Ju-248, 249, S-376, 377  
 The Roche Hospital Pharmacy Board, S-372, 373, O-436, 437  
 Roche Retrieval Program, F-55, Mr-101, Ap-154  
 Valium, O-440, 441; Valium Quick Reference File, Ag-368 and between 368 and OBC  
 Winners of 1972 Roche Hospital Pharmacy Research Grants, Ju-246, 247, Ag-366, 367  
 A. H. Robins Company  
 Sign of Change, F-51, Ap-147, D-531  
 For the Next 8 Hours It's His Baby, Mr-99  
 Mystery Man, Ma-195  
 St. John's University  
 To the Clinical Pharmacist, Ap-190  
 Smith Kline & French Laboratories  
 Five More Products, N-OBC  
 Plans For a Good Lecture, N-487  
 S-K Line Expands Again, Ma-OBC  
 Thorazine and Compazine, Jl-OBC, S-OBC  
 When P&T Asks You About ANCEF, N-488, 489; D-534-535  
 University of Alberta  
 Graduate Studies in Pharmaceutical Sciences, Ja-48  
 University of Iowa  
 Drug Therapy Consultant position open, Ag-350  
 Wiley-Interscience  
 Summer Book Selections, Jl-291